This article is more than 5 years old. Information may no longer be current.

VIDEO: Option B+ discussed at CROI 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — Elaine J. Abrams, MD, professor of pediatrics and epidemiology at Columbia University Medical Center, discusses highlights from a session on pediatric HIV infection presented at the 2016 Conference on Retroviruses and Opportunistic Infections.

The studies presented during the session evaluated outcomes of the Option B+ approach in Africa, where all pregnant and breast-feeding women are assigned ART, as well as the effects of ART on infants.  

Disclosure: Abrams reports serving on the advisory board for Merck and reports being an investigator for the Safe Generation study, which received donated drugs from Gilead Sciences and Merck.